Anelixis was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (
), a nonprofit biotechnology organization dedicated to developing effective treatments for ALS.
In recent years the economics of developing transformative new treatments for patients has become challenging for the pharmaceutical industry. This has resulted in massive restructuring of the pharmaceutical business with significant down sizing in preclinical drug development. In the absence of basic research and drug discovery occurring in pharmaceutical companies both these companies as well as the patient community are now relying on other organizations to drive basic research and early drug development. In order to de risk this early stage of development Anelixis Therapeutics will leverage over ten years of expertise in target validation and lead molecule optimization at ALS TDI.
ALS TDI can assist in preclinical proof of concept studies with established in vitro and in vivo assay systems. Anelixis thus has the ability to in license lead candidates generated at ALS TDI as well as to in license third party opportunities and validate these opportunities using ALS TDI’s established infrastructure.
Contact us for more information
© 2017 Anelixis Therapeutics, LLC.